NSE · KPL
Kwality Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹162 Cr with net profit ₹26 Cr — a 15.79% net margin, versus 13.31% the period before.
Shareholding
As of 2026-06-30
- Promoter54.86%
- Public41.44%
- FII3.13%
- DII0.56%
13,279 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.43× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ST-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #41 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,42,821 Cr | 35.05 | 5.3 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,232 Cr | 22.78 | 4.1 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,677 Cr | 30.93 | 3.21 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,026 Cr | 96.04 | 19.82 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹96,031 Cr | 25.4 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,446 Cr | 29.62 | 2.51 | 11.07% | 9.73% |
| Lupin Limited | ₹95,047 Cr | 15.96 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹93,059 Cr | 43.62 | 5.71 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,160 Cr | 21.84 | 6.48 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,517 Cr | 87 | 1.84 | 1.14% | 2.89% |
| Kwality Pharmaceuticals Limited(this company) | ₹3,650 Cr | 44.71 | 11.04 | 20.31% | 14.63% |
AI analysis
AI-generated · google/gemini-2.5-flashKwality Pharmaceuticals Limited (KPL) is listed in the Pharmaceuticals sector. The company has a market capitalization of Rs 2788 Cr. As of March 31, 2026, promoter holding stands at 54.8666% with no pledged shares. The company reported a profit margin of 13.39%.
Positives
- +The Return on Equity (ROE) is 20.31%, indicating efficient use of shareholder funds.
- +The Return on Capital Employed (ROCE) is 21.4553%, suggesting effective utilization of capital.
- +The debt-to-equity ratio is 0.43, which is relatively low.
- +Promoter holding of 54.8666% suggests significant commitment from the owners.
- +There are no pledged promoter shares (0% pledged).
Negatives
- −Annual revenue growth data is not available.
- −Quarterly EPS data is not available.
- −The dividend yield is 0%, indicating no dividend payouts.
- −No historical shareholding data for DII, FII, or promoter holdings is available prior to March 2026.
- −A significant portion of shares (41.9838%) is held by the public, which may lead to higher price volatility.
Financial performance
In the annual period ending March 2025, Kwality Pharmaceuticals Limited reported revenue of Rs 372.1171 Cr and a net profit of Rs 39.8451 Cr. For the most recent quarter ending March 2026, the company generated revenue of Rs 157.11 Cr and a net profit of Rs 25.3 Cr. Over the last three quarters of 2025 (June, Sept, Dec), revenue has shown incremental growth from Rs 111.48 Cr to Rs 123.44 Cr.
Profitability & Returns
Kwality Pharmaceuticals Limited demonstrates a Return on Equity (ROE) of 20.31% and a Return on Capital Employed (ROCE) of 21.4553%. The Earnings Per Share (EPS) for the company is Rs 65.5. The company's profit margin stands at 13.39%.
Balance Sheet
The company has a Book Value of Rs 318.8. The debt-to-equity ratio is 0.43, indicating a manageable level of debt relative to equity. There is no dividend yield reported for the company (0%).
Ownership & Pledges
As of March 31, 2026, the promoter holding in Kwality Pharmaceuticals Limited is 54.8666%. Public shareholding is 41.9838%. The total number of shareholders is 10555, and there are no pledged promoter shares (0%).
Data as of — price: 2026-09-10 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Kwality Pharmaceuticals Limitedshare price & fundamentals